An observational study in Glioma, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by University of California, San Francisco · Observational
This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
PRIMARY OBJECTIVE:
OUTLINE:
Participants with and without glioma will be evaluated to develop a robust strategy for obtaining 2H-glucose metabolism in twenty healthy participants (cohort 1) and thirty participants with glioma (cohort 2), while the remaining thirty glioma participants will be studied at baseline and after completion of non-investigational therapy (cohort 3).
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
This study's planned enrollment of 80 is close to the median of 88 across 238 observational studies indexed under Glioma.
Browse Glioma studies →University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Healthy adults and adult patient referrals from the UCSF Neuro-Oncology Service and Department of Neurological Surgery.
Participants must be >= 18 years old
Exclusion Criteria:
Participants must be excluded from participating in this study if they are not able to comply with the study and/or follow-up procedures.
Twenty healthy controls for will have 2H-glucose metabolism in measured for development of robust strategy in optimizing acquisition parameters.
Drug: Deuterated Glucose · Procedure: Magnetic Resonance Imaging (MRI) · Procedure: Blood Sample · Procedure: MR spectroscopy (MRS)
Thirty participants with glioma who may or may not have received prior treatment for testing the optimized imaging protocol developed in Cohort 1.
Drug: Deuterated Glucose · Procedure: Magnetic Resonance Imaging (MRI) · Procedure: Blood Sample · Procedure: MR spectroscopy (MRS)
Thirty participants who will receive non-investigational treatment for glioma enrolled to test the evaluation for treatment induced metabolic changes at baseline and post- non-investigational treatment.
Drug: Deuterated Glucose · Procedure: Magnetic Resonance Imaging (MRI) · Procedure: Blood Sample · Procedure: MR spectroscopy (MRS)
Given orally
Also known as: Hydrogen gas (H2) glucose, [6,6'-2H2] glucose
Imaging procedure performed at University of California, San Francisco
Also known as: MRI
Capillary blood from the fingertip
Imaging procedure performed at University of California, San Francisco
Also known as: MRS
Signal-to-noise ratio (Cohort 1 & 2)
The signal-to-noise ratio (SNR) in metabolite concentrations will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the regions of interest (ROIs) of the anatomic and metabolic lesions on the imaging scan. Peaks with SNR \> 5.0 are considered detectable
Time frame: Day of imaging (1 day)
Mean difference in metabolite concentrations (Cohort 1 & 2)
Mean difference in metabolite concentrations of 2H labeling of these metabolites will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the ROIs of the anatomic and metabolic lesions.
Time frame: Day of imaging (1 day)
Mean difference in fractional enrichment (Cohort 1 & 2)
Mean difference in fractional enrichment of 2H labeling of these metabolites will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the ROIs of the anatomic and metabolic lesions.
Time frame: Day of imaging (1 day)
Mean metabolic turnover over time (Cohort 3)
Estimates of the extent of change over time following non-investigational treatment obtained at the baseline and one repeated after receiving treatment will be compared.
Time frame: Up to 21 days after the completion of non-investigational treatment
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco